Drug resistance of EGFR-TKI for non-small cell lung cancer

Jun Liu, Changli Wang

    Research output: Contribution to journalArticle


    The incidence of lung cancer ranks the first among malignancies in China. Studies on molecular-targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have atracted more attention. However, many patients with non-small cell lung cancer (NSCLC) manifest primary symptoms at the beginning of therapy; other patients develop drug resistance after they receive EGFR-TKI treatment for a period. This review describes the progress on drug resistance mechanisms of EGFR-TKIs at a molecular level and the significance of such inhibitors in clinical application.

    Original languageEnglish (US)
    Pages (from-to)1207-1209
    Number of pages3
    JournalChinese Journal of Clinical Oncology
    Issue number19
    StatePublished - Oct 15 2013


    • Epidermal growth factor receptor
    • Non-small cell lung cancer
    • Tyrosine kinase inhibitor (EGFR-TKI)

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Drug resistance of EGFR-TKI for non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this